ArticleMedical science monitor : international medical journal of experimental and clinical research2015
Serum galectin-3 as a potential marker for gastric cancer.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Clinical utility of GAL-8, ITGΒ-1, and HIF-1α as non-invasive diagnostic and prognostic biomarkers for assessing glioma.Journal of neuro-oncology · 2025Article
- Review
- Evaluation of serum galectin-3 concentration as a potential biomarker in exudative-type age-related macular degeneration.Scientific reports · 2024Article
- Evaluation of Galectin-3 in Dogs with Atrial Fibrillation.Animals : an open access journal from MDPI · 2024Article
- Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure.JACC. CardioOncology · 2023Article
- Gal-3 Protein Expression and Localization in Prostate Tumours.Current oncology (Toronto, Ont.) · 2023Article
- Immunomodulation exerted by galectins: a land of opportunity in rare cancers.Frontiers in immunology · 2023Review
- Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions.Methods in molecular biology (Clifton, N.J.) · 2022Review
- Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis.Diagnostics (Basel, Switzerland) · 2021Review
- Gastroprotection against Rat Ulcers byBiomolecules · 2021Article
- Circulating Galectin-3 Evaluation in Dogs With Cardiac and Non-cardiac Diseases.Frontiers in veterinary science · 2021Article
- LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.Frontiers in medicine · 2020Article
- Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study.International journal of breast cancer · 2020Article
- Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.Cancer medicine · 2019Article
- Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).International journal of molecular medicine · 2018Review
- Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies.Cancer cell international · 2018Article
- Association of Serum Galectin-3 with the Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer.Oncotarget · 2016Article
- Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer.Biomedical reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe identification of cancer biomarkers can advance the possibility for early detection and better monitoring of tumor progression. The aim of this study was to assess the diagnostic and prognostic value of serum galectin-3(Gal-3) in patients with gastric cancer (GC). MATERIAL AND
methodsWe measured serum Gal-3 levels using ELISA method in 87 patients with GC, 53 patients with benign gastric lesions, and 51 healthy controls.
resultsSerum levels of Gal-3 in patients with GC were significantly higher than those in benign disease patients and healthy controls (P<0.001), but no difference was found between benign disease patients and healthy controls (P=0.635). Additionally, serum Gal-3 level was associated with lymph node metastasis (P=0.001) and distant metastasis (P<0.001), whereas it was not related to gender (P=0.204), age (P=0.269), tumor size (P=0.399), location (P=0.715), TNM stage (P=0.385), differentiation (P=0.135), or invasion depth (P=0.273). The Kaplan-Meier survival analysis revealed that overall survival rates in patients with high Gal-3 levels were not significantly different that those with low Gal-3 levels (P=0.099).
conclusionsResults of the current study suggests that serum Gal-3 represents a potential diagnostic marker for patients with GC, and may be an adjunct to determine the individual prognosis of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.